Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus low-dose rituximab for antibody-mediated rejection after kidney transplantation
IRCT201508103043N10Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in humoral rejection (2 arms), sponsored by Tehran University of Medical Sciences. Started Feb 2016; status: completed.
02
Drugs
rituximab
03
Conditions
humoral rejection
Beyond the preview
Go deeper on IRCT201508103043N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201508103043N10.